ARDELYX, INC.
ARDX US0396971071
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -83% | 142% | 131% | -16% | -3% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Williams Laura A SR OFF |
6.12 USD |
30,000 Sold |
183,630 USD |
26/08/2025 | 26/08/2025 |
| Williams Laura A SR OFF |
6.12 USD |
50,000 Sold |
306,050 USD |
26/08/2025 | 26/08/2025 |
| Grammer Elizabeth A O |
5.93 USD |
5,841 Sold |
34,647 USD |
21/08/2025 | 21/08/2025 |
| Raab Michael CEO |
5.93 USD |
45,687 Sold |
271,002 USD |
21/08/2025 | 21/08/2025 |
| Williams Laura A SR OFF |
5.93 USD |
6,261 Sold |
37,138 USD |
21/08/2025 | 21/08/2025 |
| Foster Eric Duane CCO |
5.93 USD |
15,308 Sold |
90,802 USD |
21/08/2025 | 21/08/2025 |
| Kelliher Mike CBO |
5.93 USD |
5,417 Sold |
32,132 USD |
21/08/2025 | 21/08/2025 |
| Renz Justin A CFO |
5.93 USD |
7,037 Sold |
41,741 USD |
21/08/2025 | 21/08/2025 |
| Renz Justin A CFO |
5.93 USD |
7,037 Sold |
41,741 USD |
21/08/2025 | 21/08/2025 |
| Mott David M O |
3.63 USD |
200,000 Bought |
725,880 USD |
16/06/2025 | 16/06/2025 |